Long-term celiprolol therapy lowers fasting plasma leptin levels

Cardiovascular Drugs and Therapy

Volumn 14, Issue 1, 2000, Pages 67-75

  Malminiemi, Kimmo ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Celiprolol; Dyslipidemia; Glucose tolerance; Insulin sensitivity; Leptin; Metabolic syndrome

Indexed keywords

CELIPROLOL; CHOLESTEROL; GLUCOSE; INSULIN; LEPTIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; CELIPROLOL; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; LEPTIN; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE;

EID: 0034052791     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007847306219     Document Type: Article

References (48)

1. 1. Remesar X, Rafecas I, Fernandez-Lopez JA, Alemany M. Leptin. Med Res Rev 1997;17:225-234.
2. 2. Slieker LJ, Sloop KW, Surface PL, et al. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996;271:5301-5304.
3. 3. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-623.
4. 4. Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82:2771-2776.
5. 5. Reaven GM. Syndrome X. Clin Diabetes 1994;12:32-36.
6. 6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
7. 7. Lefebre PJ. Syndrome X. Diabetes Nutr Metab 1993;6: 51-65.
8. 8. Haffner SM, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL, Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997;21:393-399.
9. 9. Milne RJ, Buckley MMT. Celiprolol - An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs 1991; 41:941-969.
10. 10. Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995;9:295-304.
11. 11. Malminiemi K, Lahtela J, Malminiemi O, Ala-Kaila K, Huupponen R. Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. J Cardiovasc Pharmacol 1998;31:140-145.
12. 12. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970;43:891-915.
13. 13. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. Radioimmunoassay of leptin in human plasma. Clin Chem 1996;42:942-926.
14. 14. Hintze JL. BMDP SOLO Statistical Programs. Version 4.0 BMDP Statistical Software Inc., Los Angeles, CA, USA, 1991.
15. 15. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design, 3rd ed. New York: McGraw Hill, 1991:432-468.
16. 16. Zar JH. Biostatistical Analysis, 2nd ed. Englewood Cliffs, NJ: Prentice-Hall International, 1984:206-217.
17. 17. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
18. 18. Lönqvist F, Nordfors L, Jansson M, Thorne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997;99:2398-2404.
19. 19. Malminiemi K, Lahtela JT, Huupponen R. Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. Int J Clin Pharmacol Ther 1995;33: 156-163.
20. 20. Van Mieghem W. Evaluation of glucose tolerance during treatment with celiprolol in patients with mild arterial hypertension without diabetes mellitus. The Genker General Practitioners. Acta Clin Belg 1997;52:360-366.
21. 21. Dhein S, Titzer S, Wallstein M, et al. Celiprolol exerts microvascular dilatation by activation of beta-2 adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1992;346:27-31.
22. 22. Santti E, Rouru J, Koulu M, et al. Effect of chronic celiprolol treatment on brown adipose tissue thermogenesis in genetically obese Zucker rats. Abstract in 6th European Congress on Obesity, June 1995, Copenhagen. Int J Obes 1995;19 (Suppl. 2):146.
23. 23. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity ofantagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol 1992;34:337-343.
24. 24. Tung LH, Jackman G, Campbell B, Louis S, Iakovidis D, Louis WJ. Partial agonist activity of celiprolol. J Cardiovasc Pharmacol 1993;21:484-488.
25. 25. Malminiemi K, Laine H, Knuuti MJ, et al. Acute effects of celiprolol on muscle blood flow and insulin sensitivity: studies using [150]-water, [18F]-fluorodeoxyglucose and positron emission tomography. Eur J Clin Pharmacol 1997;52:19-26.
26. 26. Caruso FS, Berger BM, Darragh A, Weng T, Vukovich R. Effect of celiprolol, a new beta 1-alpha 2 blocker, on the cardiovascular response to exercise. J Clin Pharmacol 1986;26:32-38.
27. 27. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systematic hypertension, and effects of celiprolol. Am J Cardiol 1994;74:901-905.
28. 28. Tolvanen JP, Wu X, Kahonen M, et al. Effect of celiprolol therapy on arterial dilatation in experimental hypertension. Br J Pharmacol 1996;119:1137-1144.
29. 29. Schweizer J, Kaulen R, Nierade A, Altmann E. Beta-blockers and nitrates in patients with peripheral arterial occlusive disease: long-term findings. Vasa 1997;26:43-46.
30. 30. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.
31. 31. Avogaro A, Piarulli F, Valerio A, et al. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 1997;46:1040-1046.
32. 32. Laine H, Knuuti MJ, Ruotsalainen U, et al. Insulin resistance in essential hypertension is characterized by impaired insulin stimulation of blood flow in skeletal muscle. J Hypertens 1998;16:211-219.
33. 33. Rayner DV, Simon E, Duncan JS, Trayhurn P. Hyperleptinaemia in mice induced by administration of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine. FEBS Lett 1998;429:395-398.
34. 34. Weidmann P, Bohlen L, de Courten M. Insulin resistance and hyperinsulinemia in hypertension. J Hypertens Suppl 1995;13:S65-S72.
35. 35. Capaldo B, Napoli R, Guida R, et al. Forearm muscle insulin resistance during hypoglycemia: role of adrenergic mechanisms and hypoglycemia per se. Am J Physiol 1995;268: E248-E254.
36. 36. Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs: an update. Drug Safety 1993; 9:272-279.
37. 37. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: Mc Graw Hill, 1997:746-749.
38. 38. Auwerx J, Staels B. Leptin. Lancet 1998;351:737-742.
39. 39. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 1997;46:717-719.
40. 40. Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF. Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab 1996;81: 4162-4165.
41. 41. Kennedy A, Gettys TW, Watson P, et al. The metabolic significance of leptin in humans: gender-based differencesin relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997;82:1293-1300.
42. 42. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272:6093-6096.
43. 43. Kruszynska YT. Normal metabolism: the physiology of fuel homeostasis. In: Pickup J, Williams G, eds. Textbook of Diabetes. London: Blackwell Science, 1997: Chapter 11.
44. 44. Remesar X, Rafecas I, Fernandez-Lopez JA, Alemany M. Is leptin an insulin counter-regulatory hormone? FEBS Lett 1997;402:9-11.
45. 45. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-991.
46. 46. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 1998;25:175-184.
47. 47. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996;274:1185-1188.
48. 48. Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF. Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 1997;46:1087-1093.